Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma

Qingqing Zhou, Athena F Phoa, Ramzi H. Abbassi, Monira Hoque, Tristan A. Reekie, Josep S. Font, Renae M Ryan, Brett William Stringer, Bryan W Day, Terrance G. Johns, Lenka Munoz, Michael Kassiou

Research output: Contribution to journalArticleResearchpeer-review

17 Citations (Scopus)

Abstract

The DYRK family contains kinases that are up-regulated in malignancy and control several cancer hallmarks. To assess the anticancer potential of inhibitors targeting DYRK kinases, we developed a series of novel DYRK inhibitors based on the 7-azaindole scaffold. All compounds were tested for their ability to inhibit DYRK1A, DYRK1B, DYRK2, and the structurally related CLK1. The library was screened for anticancer efficacy in established and stem cell-like glioblastoma cell lines. The most potent inhibitors (IC50 ≤ 50 nM) significantly decreased viability, clonogenic survival, migration, and invasion of glioblastoma cells. Target engagement was confirmed with genetic knockdown and the cellular thermal shift assay. We demonstrate that DYRK1A’s thermal stability in cells is increased upon compound treatment, confirming binding in cells. In summary, we present synthesis, structure-activity relationship, and efficacy in glioblastoma-relevant models for a library of novel 7-azaindoles.

Original languageEnglish
Pages (from-to)2052-2070
Number of pages19
JournalJournal of Medicinal Chemistry
Volume60
Issue number5
DOIs
Publication statusPublished - 9 Mar 2017
Externally publishedYes

Cite this

Zhou, Qingqing ; Phoa, Athena F ; Abbassi, Ramzi H. ; Hoque, Monira ; Reekie, Tristan A. ; Font, Josep S. ; Ryan, Renae M ; Stringer, Brett William ; Day, Bryan W ; Johns, Terrance G. ; Munoz, Lenka ; Kassiou, Michael. / Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma. In: Journal of Medicinal Chemistry. 2017 ; Vol. 60, No. 5. pp. 2052-2070.
@article{5856089b63744307821e49515d3364d9,
title = "Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma",
abstract = "The DYRK family contains kinases that are up-regulated in malignancy and control several cancer hallmarks. To assess the anticancer potential of inhibitors targeting DYRK kinases, we developed a series of novel DYRK inhibitors based on the 7-azaindole scaffold. All compounds were tested for their ability to inhibit DYRK1A, DYRK1B, DYRK2, and the structurally related CLK1. The library was screened for anticancer efficacy in established and stem cell-like glioblastoma cell lines. The most potent inhibitors (IC50 ≤ 50 nM) significantly decreased viability, clonogenic survival, migration, and invasion of glioblastoma cells. Target engagement was confirmed with genetic knockdown and the cellular thermal shift assay. We demonstrate that DYRK1A’s thermal stability in cells is increased upon compound treatment, confirming binding in cells. In summary, we present synthesis, structure-activity relationship, and efficacy in glioblastoma-relevant models for a library of novel 7-azaindoles.",
author = "Qingqing Zhou and Phoa, {Athena F} and Abbassi, {Ramzi H.} and Monira Hoque and Reekie, {Tristan A.} and Font, {Josep S.} and Ryan, {Renae M} and Stringer, {Brett William} and Day, {Bryan W} and Johns, {Terrance G.} and Lenka Munoz and Michael Kassiou",
year = "2017",
month = "3",
day = "9",
doi = "10.1021/acs.jmedchem.6b01840",
language = "English",
volume = "60",
pages = "2052--2070",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "AMER CHEMICAL SOC",
number = "5",

}

Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma. / Zhou, Qingqing; Phoa, Athena F; Abbassi, Ramzi H.; Hoque, Monira; Reekie, Tristan A.; Font, Josep S.; Ryan, Renae M; Stringer, Brett William; Day, Bryan W; Johns, Terrance G.; Munoz, Lenka; Kassiou, Michael.

In: Journal of Medicinal Chemistry, Vol. 60, No. 5, 09.03.2017, p. 2052-2070.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma

AU - Zhou, Qingqing

AU - Phoa, Athena F

AU - Abbassi, Ramzi H.

AU - Hoque, Monira

AU - Reekie, Tristan A.

AU - Font, Josep S.

AU - Ryan, Renae M

AU - Stringer, Brett William

AU - Day, Bryan W

AU - Johns, Terrance G.

AU - Munoz, Lenka

AU - Kassiou, Michael

PY - 2017/3/9

Y1 - 2017/3/9

N2 - The DYRK family contains kinases that are up-regulated in malignancy and control several cancer hallmarks. To assess the anticancer potential of inhibitors targeting DYRK kinases, we developed a series of novel DYRK inhibitors based on the 7-azaindole scaffold. All compounds were tested for their ability to inhibit DYRK1A, DYRK1B, DYRK2, and the structurally related CLK1. The library was screened for anticancer efficacy in established and stem cell-like glioblastoma cell lines. The most potent inhibitors (IC50 ≤ 50 nM) significantly decreased viability, clonogenic survival, migration, and invasion of glioblastoma cells. Target engagement was confirmed with genetic knockdown and the cellular thermal shift assay. We demonstrate that DYRK1A’s thermal stability in cells is increased upon compound treatment, confirming binding in cells. In summary, we present synthesis, structure-activity relationship, and efficacy in glioblastoma-relevant models for a library of novel 7-azaindoles.

AB - The DYRK family contains kinases that are up-regulated in malignancy and control several cancer hallmarks. To assess the anticancer potential of inhibitors targeting DYRK kinases, we developed a series of novel DYRK inhibitors based on the 7-azaindole scaffold. All compounds were tested for their ability to inhibit DYRK1A, DYRK1B, DYRK2, and the structurally related CLK1. The library was screened for anticancer efficacy in established and stem cell-like glioblastoma cell lines. The most potent inhibitors (IC50 ≤ 50 nM) significantly decreased viability, clonogenic survival, migration, and invasion of glioblastoma cells. Target engagement was confirmed with genetic knockdown and the cellular thermal shift assay. We demonstrate that DYRK1A’s thermal stability in cells is increased upon compound treatment, confirming binding in cells. In summary, we present synthesis, structure-activity relationship, and efficacy in glioblastoma-relevant models for a library of novel 7-azaindoles.

UR - http://www.scopus.com/inward/record.url?scp=85015009465&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.6b01840

DO - 10.1021/acs.jmedchem.6b01840

M3 - Article

VL - 60

SP - 2052

EP - 2070

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 5

ER -